Two-year partnership extension for Maxigesic

Market-leading Kiwi pain relief brand Maxigesic has re-signed for another two years with the One New Zealand Warriors as the club’s official pain relief partner.

Maxigesic will feature on the front of the playing shorts of the NRL and NRLW sides while it will also continue to be the presenting partner for the club’s weekly recovery report.

“We’re truly grateful for what Maxigesic has done for the club since joining us as a new partner in 2024 and we’re thrilled to have them on board for a further two years,” said One New Zealand Warriors COO marketing and commercial Glenn Harris.

Maxigesic, developed and marketed by New Zealand-based AFT Pharmaceuticals, continues to be a major focus in Australasia and the rest of the world, with a landmark United States launch for Maxigesic tablets coming in early 2026, following on from the launch of Maxigesic IV within the US market.

“With Maxigesic continuing to be the #1 paracetamol/ibuprofen combination in Australia, AFT’s largest market, we feel fully aligned with the One New Zealand Warriors’ goal of taking on the best that Australia has to offer and beating them in the toughest rugby league competition in the world,” said AFT Pharmaceuticals CEO Hartley Atkinson.

“As a Kiwi brand that has enjoyed great success in the Australian market with Maxigesic, we are excited to be partnering again with the Warriors to help them reach their ultimate goals in both the NRL and NRLW competitions over the next two seasons.

“We’re delighted to have signed on for another two years as the club’s official pain relief partner and we’re proud to have our Maxigesic name on the playing shorts for both the NRL and NRLW teams in both competitions.”

AFT Pharmaceuticals has continued to go from strength to strength in recent years. Listed on both the ASX and NZX, it has significantly expanded its international operations with the development of a series of international business hubs around the world.

Along with New Zealand and Australia, AFT Pharmaceuticals has extended its global footprint to include the United States, Canada, China, Singapore, Malaysia, Hong Kong, South Africa, Europe and the United Kingdom.

AFT Pharmaceuticals has recently recorded its 10th consecutive first half-year revenue increase and remains on target to hit $300m revenue for the 2026-2027 financial year.

• Maxigesic® was developed as a smarter alternative that provides faster and more effective pain relief than other analgesics, particularly those containing opioids, and is clinically proven to provide 78 per cent more effective pain relief than Paracetamol alone and 36 per cent more effective pain relief than Ibuprofen alone¹.
• Ref. 1: Two tablets of Maxigesic® four times per day provides more effective pain relief than a full daily dose of Paracetamol or Ibuprofen given in four divided doses. Claim based on trials of postoperative pain relief after removal of 1–4 wisdom teeth. Daniels et al (2018). Research sponsored by AFT Pharmaceuticals. Do not use if you have a stomach ulcer. Always read the label. Use only as directed. Incorrect use can be harmful. If symptoms persist consult your healthcare professional. AFT Pharmaceuticals, Auckland. Patent No. 552181. *Source: IQVIA Total Australian Pharmacy sales data – MAT to 30/11/25

More information: https://www.aftpharm.com/